Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | HPGD | P15428 | 5/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.36 |
| ▸ | FEN1 | P39748 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6678771 | 0.86 | ALDH1A1 (0.39) | ALDH1A1SMN1; SMN2LMNA | |
| SCHEMBL6685457 | 0.83 | ABCB1 (0.35) | ALDH1A1HPGDKDM4ESMN1; SMN2LMNA | |
| SCHEMBL6679496 | 0.79 | MMP1 (0.46) | ALDH1A1KDM4ESMN1; SMN2LMNAUSP2 | |
| SCHEMBL6682847 | 0.78 | MAPT (0.47) | ALDH1A1HPGDKDM4EUSP2 | |
| SCHEMBL6679185 | 0.76 | SMN1; SMN2 (0.45) | ALDH1A1HPGDSMN1; SMN2LMNACYP3A4 | |
| SCHEMBL7061509 | 0.76 | HPGD (0.43) | ALDH1A1HPGDKDM4ESMN1; SMN2LMNA | |
| SCHEMBL6685031 | 0.76 | HPGD (0.43) | ALDH1A1HPGDKDM4ESMN1; SMN2LMNA | |
| SCHEMBL6678347 | 0.76 | ALDH1A1 (0.43) | ALDH1A1HPGDKDM4ESMN1; SMN2LMNA | |
| SCHEMBL10963471 | 0.65 | ALDH1A1 (0.51) | ALDH1A1HPGDKDM4ESMN1; SMN2LMNA | |
| SCHEMBL6681995 | 0.65 | SMN1; SMN2 (0.48) | ALDH1A1HPGDKDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | ROARK WILLIAM HOWARD (US) | 2004-11-11 | — | — | US | disclosed |
| WO-2004014921-A1 | 5,6-FUSED URACIL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224951-A1 | 5,6-Fused uracil derivatives as matrix metalloproteinase inhibitors | MMP9, MMP13, MMP25 | ALDH1A1 812/4885HPGD 877/4885KDM4E 819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.